



Figure 1



| Plasmid | Leader | Gene | Promoter | Enhancer | Intron | Terminator |
|---------|------------------------------|-----------------------------------|----------|----------|--------|------------|
| VR4700 | tissue plasminogen activator | influenza A/PR/8/34 nucleoprotein | CMV | CMV | CMV-A | mRBG |
| VR5900 | hen egg lysozyme | hen egg lysozyme | CMV | CMV | CMV-A | mRBG |
| VR1412 | not secreted | E. coli Lac Z | CMV | CMV | CMV-A | BGH |
| VR1623 | mouse immunoglobulin | mouse Ig/humanFc | CMV | CMV | CMV-A | BGH |
| VR1904 | human factor IX | human factor IX | CMV | CMV | CMV-A | BGH |

Figure 2


Cytofectin Structures



DDRIE
DLRIE
DMRIE
DMORIE
DORIE



GAP-DLRIE
GAP-DMRIE
GAP-DMORIE
GAP-DPRIE



DOSPA

Co-Lipid Structures




DOPEDMPEDPyPE

Figure 3

Cytofectin Structural Elements Determine the Level of Antibody Stimulation

Cytofectin Geometric Mean Titer / pDNA Geometric Mean Titer






Figure 4


Cytotoxins Are Differentially Enhanced By Using DPyPE Instead of DOPE





Vaccine, Hartikka et al., Figure 5




Vaccine, Hartikka et al., Figure 6




Vaccine, Hartikka et al., Figure 4




Vaccine, Hartikka et al., Figure 8



Vaccine, Hartikka et al., Figure 9



Vaccine, Hartikka et al., Figure 10




[illegible]

Figure 12






Figure 13

A.



B.




T09260" +092E60

09/937604

Figure 14

A.



B.

